Physician profile
Deanna Johnson
NPI 1659309631
$40,915.90
in general payments reported to CMS, 2019-2025
68 companies · $8,659 in 2025
The $8,659 reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,417 · 2022: $4,781 · 2023: $12K · 2024: $7,566 · 2025: $8,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21K · Travel and Lodging: $3,701 · Consulting Fee: $3,560 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21,302.32 |
| Travel and Lodging | $3,700.61 |
| Consulting Fee | $3,560.00 |
| Education | $155.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $6,006.56 | 2021-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $5,576.05 | 2023-2025 | Briumvi |
| Livanova USA, INC. | $3,292.18 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $2,434.65 | 2021-2025 | |
| Biogen, INC. | $2,306.98 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Abbott Laboratories | $2,001.69 | 2021-2025 | Infinity |
| Novartis Pharmaceuticals Corporation | $1,308.52 | 2021-2025 | Kesimpta |
| Pfizer INC. | $1,229.23 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $1,145.72 | 2021-2025 | Ultomiris, Soliris |
| Boston Scientific Corporation | $1,095.72 | 2022-2024 | Vercise |
| Supernus Pharmaceuticals, INC. | $1,094.47 | 2021 | |
| Genzyme Corporation | $955.91 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $875.35 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $730.59 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Amgen INC. | $718.48 | 2021-2025 | Uplizna, Aimovig |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $609.53 | 2021-2025 | |
| Genentech USA, INC. | $606.28 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $598.06 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $595.90 | 2021-2025 | Xcopri |
| Merz Pharmaceuticals, LLC | $581.35 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Celgene Corporation | $492.35 | 2021-2024 | Zeposia |
| Neurelis, INC. | $458.22 | 2021-2025 | Valtoco |
| Lilly USA, LLC | $442.55 | 2021-2025 | Kisunla, Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $410.54 | 2021 | |
| Acorda Therapeutics, INC | $400.37 | 2021-2023 | Inbrija |
| E.R. Squibb & Sons, L.L.C. | $370.62 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $366.91 | 2021-2025 | Nuplazid, Daybue |
| Eisai INC. | $364.80 | 2021-2024 | |
| Tanabe Pharma America, INC. | $289.09 | 2021-2025 | Radicava |
| Biohaven Pharmaceutical Holding Company LTD. | $285.36 | 2022 | |
| Lundbeck LLC | $270.67 | 2021-2025 | Vyepti, Rexulti |
| Grt US Holding, INC. | $209.37 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $189.47 | 2023-2024 | Rexulti, Nuedexta |
| Allergan, INC. | $158.13 | 2021 | |
| Mallinckrodt Hospital Products INC. | $152.73 | 2021-2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $143.96 | 2023-2025 | Firdapse, Fycompa |
| Axsome Therapeutics, INC. | $141.57 | 2025 | Symbravo |
| Medtronic, INC. | $138.24 | 2025 | Percept PC Brainsense |
| Janssen Biotech, INC. | $133.82 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $130.82 | 2022-2025 | Dysport |
| Ani Pharmaceuticals, INC. | $120.68 | 2022-2025 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $115.27 | 2022-2023 | Panzyga |
| Harmony Biosciences LLC | $108.48 | 2023-2025 | Wakix |
| Kyowa Kirin, INC. | $107.46 | 2021-2024 | Poteligeo, Nourianz |
| Sunovion Pharmaceuticals INC. | $100.56 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.38 | 2024 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $96.15 | 2021-2023 | Austedo Xr |
| Csl Behring | $89.23 | 2021-2025 | Hizentra |
| Alnylam Pharmaceuticals INC. | $78.29 | 2021-2024 | Amvuttra |
| Mdd US Operations, LLC | $73.15 | 2022 | |
| Greenwich Biosciences, INC. | $65.79 | 2021 | |
| Vanda Pharmaceuticals INC. | $53.22 | 2021-2025 | Ponvory |
| Amneal Pharmaceuticals LLC | $52.57 | 2022-2023 | Rytary |
| Avion Pharmaceuticals | $48.26 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $41.80 | 2022 | |
| Philips North America LLC | $41.51 | 2023 | |
| Grifols USA, LLC | $39.98 | 2021 | |
| Banner Life Sciences, LLC | $34.48 | 2023 | |
| Janssen Scientific Affairs, LLC | $30.04 | 2024 | |
| Blueprint Medicines Corporation | $27.38 | 2024 | Ayvakit |
| Horizon Therapeutics Plc | $26.20 | 2023 | Uplizna |
| Ge Healthcare | $24.74 | 2025 | |
| Amylyx Pharmaceuticals, INC. | $24.50 | 2023 | Relyvrio |
| Avanir Pharmaceuticals, INC. | $22.74 | 2022 | |
| Springworks Therapeutics, INC. | $22.03 | 2025 | Gomekli |
| Janssen Pharmaceuticals, INC | $21.48 | 2021 | |
| Collegium Pharmaceutical, INC. | $20.56 | 2022 | |
| Life Molecular Imaging LTD | $19.16 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.